What is the main takeaway from the Living Phoenix New Yearmessage?

It signals faster commercialization of trimeric collagen POGMENT in 2026, alignment with China’s GB/T 45992-2025 standard, and Q1–Q2 ASEAN e-commerce rollout. Investors should monitor channel go-lives, R&D pilot outcomes, reorder patterns, and any clinical collaboration updates for confirmation of momentum.

How does China’s GB/T 45992-2025 affect collagen suppliers?

It elevates quality expectations by emphasizing stable triple-helix characteristics. Suppliers that meet the China collagen standard may see smoother approvals and better buyer confidence. Those that cannot prove stability and consistency risk losing shelf space as retailers and regulators tighten product requirements.

Why does the ASEAN e-commerce launch matter for investors in Australia?

It offers early readouts on demand, pricing, and unit economics across nearby growth markets. Performance in Q1–Q2 can inform inventory planning, marketing spend, and later retail expansion. For Australian brands and distributors, these signals help benchmark partnership quality and cross-border sales potential.

Where can I read more about the company update?

Coverage of the Living Phoenix New Yearmessage is available here: Macau Business report and the Laotian Times summary. Both discuss commercialization plans and regional channel timing, offering useful context for tracking 2026 milestones and regulatory positioning.

Global Market Insights

January 02: Living Phoenix flags China collagen standard, ASEAN push

ByHuzaifa Zahoor January 1, 2026January 1, 2026

The Living Phoenix New Yearmessage signals faster commercialization of trimeric collagen POGMENT in 2026, backed by new R&D agreements and an ASEAN e-commerce launch targeted for Q1 and Q2. China’s GB/T 45992-2025 sets a stable triple-helix requirement, creating a regulatory tailwind for qualified suppliers. For Australian investors, this update highlights near-term milestones, channel expansion, and potential cross-border demand in skincare and regenerative medicine. See details in the company’s message covered by source.